Literature DB >> 11038348

Sequence-specific DNA binding activity of RNA helicase A to the p16INK4a promoter.

S Myöhänen1, S B Baylin.   

Abstract

p16(INK4a) is frequently altered in human cancer, often through epigenetically mediated transcriptional silencing. However, little is known about the transcriptional regulation of this gene. To learn more about such control, we initiated studies of proteins that bind to the promoter in cancer cells that do, and do not, express the gene. We identify RNA helicase A (RHA) as a protein that binds much better to the p16(INK4a) promoter in the expressing cells. RHA has not previously been characterized to manifest sequence-specific DNA interaction but does so to the sequence 5' CGG ACC GCG TGC GC 3' in the p16(INK4a) promoter. The Drosophila homologue to RHA, maleless (Mle), functions in the fly for 2-fold activation of male X-chromosome genes. In our experimental setting, RHA induces a similar modest up-regulation of the p16(INK4a) promoter that is dependent upon its sequence-specific interaction. Mle colocalizes with hyperacetylated H4Ac16 on the X-chromosome and some autosomal loci. The decreased binding of RHA to p16(INK4a) in our cells, where the gene is transcriptionally inactive, is associated with decreased amounts of RHA that immunoprecipitate with acetylated lysine antibodies. Finally, we show RHA to be a cellular substrate for caspase-3, which decreases its sequence-specific binding to p16(INK4a) by cleavage of the N terminus. Thus, we have identified a new protein interaction with the p16(INK4a) promoter that involves an important protein for transcriptional modulation. This interaction is decreased in cancer cells, where this gene is aberrantly transcriptionally silent.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11038348     DOI: 10.1074/jbc.M004481200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

Review 1.  RNA helicases: emerging roles in viral replication and the host innate response.

Authors:  Arnaz Ranji; Kathleen Boris-Lawrie
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

2.  RNA helicase DHX9 may be a therapeutic target in lung cancer and inhibited by enoxacin.

Authors:  Shiguang Cao; Ruiying Sun; Wei Wang; Xia Meng; Yuping Zhang; Na Zhang; Shuanying Yang
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

3.  The RNA helicase DHX9 establishes nucleolar heterochromatin, and this activity is required for embryonic stem cell differentiation.

Authors:  Sergio Leone; Dominik Bär; Coenraad Frederik Slabber; Damian Dalcher; Raffaella Santoro
Journal:  EMBO Rep       Date:  2017-06-06       Impact factor: 8.807

4.  Novel, Broad Spectrum Anti-Cancer Agents Containing the Tricyclic 5:7:5-Fused Diimidazodiazepine Ring System.

Authors:  Atul Kondaskar; Shilpi Kondaskar; Raj Kumar; James C Fishbein; Nidal Muvarak; Rena G Lapidus; Mariola Sadowska; Martin J Edelman; Guus M Bol; Farhad Vesuna; Venu Raman; Ramachandra S Hosmane
Journal:  ACS Med Chem Lett       Date:  2010-12-31       Impact factor: 4.345

5.  Re-localization of nuclear DNA helicase II during the growth period of bovine oocytes.

Authors:  Vladimír Baran; Hana Kovárová; Jirí Klíma; Pavel Hozák; Jan Motlík
Journal:  Histochem Cell Biol       Date:  2005-09-27       Impact factor: 4.304

6.  Dual roles of RNA helicase A in CREB-dependent transcription.

Authors:  S Aratani; R Fujii; T Oishi; H Fujita; T Amano; T Ohshima; M Hagiwara; A Fukamizu; T Nakajima
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

7.  DHX32 expression is an indicator of poor breast cancer prognosis.

Authors:  Meng Wang; Guojun Zhang; Yajie Wang; Ruimin Ma; Limin Zhang; Hong Lv; Fang Fang; Xixiong Kang
Journal:  Oncol Lett       Date:  2016-12-14       Impact factor: 2.967

8.  dsRBM1 and a proline-rich domain of RNA helicase A can form a composite binder to recognize a specific dsDNA.

Authors:  Ming-Lung Hung; Ping Chao; Kung-Yao Chang
Journal:  Nucleic Acids Res       Date:  2003-10-01       Impact factor: 16.971

Review 9.  Multiple facets of junD gene expression are atypical among AP-1 family members.

Authors:  J M Hernandez; D H Floyd; K N Weilbaecher; P L Green; K Boris-Lawrie
Journal:  Oncogene       Date:  2008-04-21       Impact factor: 9.867

10.  DHX9 inhibits epithelial-mesenchymal transition in human lung adenocarcinoma cells by regulating STAT3.

Authors:  Xueli Yan; Jing Chang; Ruiying Sun; Xia Meng; Wei Wang; Lizhong Zeng; Boxuan Liu; Wei Li; Xuehua Yan; Chen Huang; Yongxi Zhao; Zongfang Li; Shuanying Yang
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.